Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-04

Study Completion Date

2021-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed study is a prospective, open-label, unicentric, phase IV clinical trial.

This study is design to find new efficacy biomarkers for IKERVIS® (1mg/mL ciclosporin) eye drops after 1 and 3 month after initiation of therapy. Additionally, this study intends to investigate whether IKERVIS® will help patients to better overcome situations of desiccating stress by exposing them to an adverse controlled environment (ACE) and analyzing both clinical and molecular parameters.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

NCT04144413

Dry Eye Disease With Severe Keratitis

COMPLETED PHASE3

Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis

NCT03237936

Keratitis

COMPLETED PHASE4

A Clinical Trial to Evaluate the Clinical Efficacy of Cyclosporine 0.1% (Ikervis®) for Moderate to Severe Dry Eye Patients. (IKE-03-SWITCHING)

NCT04775303

Moderate to Severe Dry Eye

UNKNOWN PHASE4

Clinical Trial for the Evaluation of Safety and Efficacy of Drop 0.4%

NCT06985875

Eye Dryness

NOT_YET_RECRUITING PHASE3

Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease

NCT05865379

Dry Eye Disease

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Dry Eye Syndromes Severe Keratitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single Group Assignment

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IKERVIS® (1mg/mL ciclosporin) eye drops

Group Type EXPERIMENTAL

IKERVIS®1mg/mL

Intervention Type DRUG

One drop of study medication once daily in each eye at bedtime during 90 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IKERVIS®1mg/mL

One drop of study medication once daily in each eye at bedtime during 90 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years.
* Diagnosis of DED with Severe Keratitis who have not improved despite regular use of tear substitutes by an ophthalmologist, at least 2 months previously.
* Not stable (as defined by the two items below) under at least 2 months of constant and regular use of artificial tears (at least 4 drops a day)
* Fluorescein corneal staining ≥ 2 (Oxford scale) in both eyes.
* DEQ-5 \> 6 points
* Use of at least 4 times daily of an ocular artificial tears.
* Any concomitant medication that may affect DED, ocular surface condition or vision, must have a start date at least 3 months prior to baseline and dosage is not expected to change during the study.
* Best corrected visual acuity (BCVA) of at least 0.1 logMar at 6 meters with each eye.
* Signature of written informed consent form and data protection form.

Exclusion Criteria

* Known allergy or sensitivity to the study product(s) or its components.
* Any ocular pathology other than DED.
* History of severe ocular inflammation other than that due to DED or infection in the 6 previous months to the study inclusion.
* Any ocular surgery or trauma that may affect corneal sensitivity and/or normal tear distribution in the 6 previous months or any ocular or systemic surgery or procedure planned during the study duration that may affect the study as assessed by principal investigator.
* History of refractive surgery in the previous 18 months.
* Contact lens use in the ONE previous month to study inclusion and during the duration of the study.
* Use of any ocular topical medication for pathologies other than DED.
* Use of any other ocular topical medication for DED other than artificial tears during the last ONE (steroids) or THREE months (ciclosporine, tacrolimus) .
* Any uncontrolled severe systemic disease that may affect the eye (except for Sjögren's syndrome)
* The start date of any systemic medication that may affect DED, ocular surface condition or vision is \< 3 months prior to baseline or a change in dosage is anticipated during the study.
* Occlusion of the lacrimal puncta either surgically or with plugs within one month prior to study, or anticipated use of the same during the study.
* Pregnancy or breastfeeding.
* Current enrolments in an investigational drug or device study or participation in such a study within 30 day of entry into this study at baseline.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No